Rezolute (RZLT) Gains FDA Nod for Pre-BLA Meeting on Pancreatic Disorder Therapy
Rezolute (RZLT) received a positive regulatory update from the FDA for its therapy targeting a rare genetic disorder of the pancreas, potentially advancing it towards an official filing. The shares saw an initial jump of over 10% following the announcement.